ZyVersa shareholders approve 150,000-share equity plan increase and up to 478,600 warrant shares

ZyVersa Therapeutics, Inc.

Elected Min Chul Park, Ph.D. as Class II director with 183,493 votes for, 13,425 withheld.
Ratified Marcum LLP as independent auditor for FY2024 with 433,670 votes for.
Approved amendment to 2022 Omnibus Equity Incentive Plan, increasing shares reserved by 150,000 to 181,795.
Approved issuance of up to 478,600 shares upon exercise of certain warrants under Nasdaq Listing Rule 5635(d).
Quorum of approx. 43% of outstanding shares (1,074,196 shares) was represented at the meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.